Medicus AI, the Vienna-based health tech company, has received a ​Class I Medical Device CE Mark for its mobile application. The CE certification mark confirms that Medicus AI conforms to the requirements of the Medical Devices Directive 93/42/EEC. The Directive outlines safety and performance requirements for medical devices in the EU.

PatchAi - a startup that offers, thanks to Artificial Intelligence and Machine Learning, an empathic virtual assistant to patients participating in clinical trials - announced that it has closed two rounds of fundraising for about 900 thousand euros in 2019. The startup's service provision has been active since December 2019 and among the first PatchAi® clients is Novartis Italia, thus confirming its position as one of the fastest rising startups in the health sector.

Brainlab, the digital medical technology company, announced the recent acquisition of VisionTree Software, Inc., a San Diego based company that develops cloud-based, patient-centric data collection and health management solutions. The acquisition re-emphasizes the Brainlab commitment to

Today, the U.S. Food and Drug Administration is issuing a safety communication informing health care providers, facilities and patients about cybersecurity vulnerabilities identified for certain GE Healthcare Clinical Information Central Stations and Telemetry Servers. These devices are primarily used in health care facilities for

VTT is launching new research activities in the area of digital health as part of the growing wellbeing and health technology ecosystem in Kuopio. The new initiative aims to create state-of-the-art research based especially on the utilisation of health data, generate new digital health innovations and establish global health technology business in Finland and the Kuopio region.

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities.

Is it possible to screen thousands of people for tuberculosis using artificial intelligence in a country where internet barely exists? It is with CAD4TB. As of October, this innovative software is used to screen people for TB in even the remotest areas of Eritrea. It has been developed by Dutch company Thirona in collaboration with the also Dutch Delft Imaging Systems.